Orphanion AG, a CRO/CMO that focuses on contract research and manufacturing services for niche active pharmaceutical ingredients (APIs), and LGM Pharma, a provider of API sourcing, warehousing and distribution services to the pharmaceutical and biotechnology industries, have finalized a partnering agreement. Under the terms of the agreement, Orphanion’s specialty services, such as production of difficult-to-synthesize molecules for niche applications, will be available to LGM Pharma clients.
 
“Access to LGM’s extensive international experience and global clientele will enable Orphanion to extend our operational reach and broaden our service portfolio in niche market segments,” said Guido Bossi, managing director, Orphanion.
 
Prasad Raje, chief executive officer, LGM Pharma, said, “We welcome the opportunity to collaborate with Orphanion, which broadens the scope of API-related products and services we can offer our global customer base, especially in the areas of complex molecules and niche indications.“